Skip to main content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Cancer Biomarker Reference Materials

Summary

NIST develops reference materials for cancer biomarkers that can be used to improve measurements of assays used in basic research and in clinical applications. The reference materials are developed in consultation with cancer experts from industry, academic, and government laboratories.  

Our team is continually working with stakeholders to develop additional reference materials to improve the measurement reliability and confidence for important cancer biomarkers.

NIST Cancer Biomarker Reference Materials:

 

Description

HER2 SRM

Figure 1. SRM 2373® Genomic DNA Standards for HER2 Measurements.

Reference materials (RMs) are an essential part of improving the quality of measurements. RMs produced by NIST and others are used ensure that the procedures and analytical measurements are working correctly using a well-characterized material with certified values.

RMs are made in large batches with assured homogeneity and stability, and thus have a clear advantage to assessing the quality of measurements over ad hoc laboratory samples. 

Another important part of the NIST quality improvements process is using well-characterized RMs to conduct interlaboratory testing. In some cases, the interlaboratory testing can be an important step in improving RMs to be better suited for the applications.

Standard reference material (SRM) 2373®: Genomic DNA Standards for HER2 Measurements

The amplification of the gene for Human Epidermal Growth Factor Receptor 2 (HER2) occurs in approximately 20 to 25% of breast cancers. The accurate measurement of this biomarker is important for the proper treatment with anti-HER2 therapeutics. Diagnostic tests like HER2 assays make it possible to select the best personalized treatment for individual patients based on the genetic makeup of their tumors. 

SRM 2373 consists of purified genomic DNA from five breast cancer cell lines with different amounts of HER2 gene (Fig. 2).

Genomic DNA from 5 human breast cancer cell lines with different amounts of amplification of the HER2 gene
Figure 2. Genomic DNA from 5 human breast cancer cell lines with different amounts of amplification of the HER2 gene.

The copy numbers of the HER2 gene and 3 reference genes (not amplified) were measured using quantitative PCR and digital PCR assays. The certified values of the components are the ratios of the HER2 gene copy number to the reference gene copy numbers. The PCR assays were validated and calibrated using SRM®2372 component A (human genomic DNA). The stability of the components was shown by repeated measurements over several years. The DNA concentration determined from absorbance and the PCR assays was provided as informational value. This SRM is available from NIST as SRM 2373®.

Use of SRM 2373 components for the validation of different NGS methods and algorithms assays used for clinical decisions for treatment of individual cancer patients.
Figure 3. Use of SRM 2373 components for the validation of different NGS methods and algorithms assays used for clinical decisions for treatment of individual cancer patients.

NIST RMs for Validation of Copy Number Measurements to Support Cancer Precision Medicine

NIST has an ongoing collaboration with the Molecular Characterization Laboratory (MCL) at the Frederick National Laboratory for Cancer Research to provide them with RMs for validation of actionable targets. SRM 2373 genomic DNA for HER2 gene copy numbers was used by MCL scientists to validate the performance of digital PCR and Next Generation Sequencing (NGS) assays for evaluating gene variations associated with an increased risk of breast cancer. The details of this work are described in the article cited below.

Reference: “Certified DNA Reference Materials to Compare HER2 Gene Amplification Measurements Using Next Generation Sequencing Methods” 
 

Diagram of the Epidermal Growth Factor Family on Cell Surfaces. These tyrosine kinase proteins are frequently mutated and amplification in many types of cancer.
Figure 4. Diagram of the Epidermal Growth Factor Family on Cell Surfaces. These tyrosine kinase proteins are frequently mutated and amplified in many types of cancer.


RM 8366: Gene Copy Number Standards for EGFR and MET

We have developed genomic DNA RM for copy number measurements of the genes for MET and EGFR (Epidermal Growth Factor Receptor). MET and EGFR are both tyrosine kinase proteins found on the surfaces of cells that response to external growth factors. Mutations or amplification of the genes for MET and EGFR can cause increased cellular signaling for cell growth or mobilization resulting in cancer. The accurate measurements of these cancer biomarkers are important for the correct diagnostics to determine the treatment, since specific therapeutics are available for both of these targets

RM 8366 consists of purified genomic DNA isolated from six different cancer cell lines with different amounts of amplification of the EGFR and MET genes (Fig.5). It is intended to harmonize the measurements of ratios of the human EGFR and MET genes to unamplified reference genes. This RM is available from NIST as RM 8366

RM 8366 Component
Figure 5. Illustration of the gene copy number for MET, and EGFR in the 6 components of RM 8366 (the error bar is the 95% prediction interval).

The reference values for the ratio of the EGFR and MET gene copy number to the copy numbers of reference genes were determined by digital PCR. Interestingly, the component E (produced from a stomach derived cell line Hs 746T) also has a MET gene mutation resulting in exon 14 skipping, a mutation commonly found in lung cancers. NGS was used to confirm the copy numbers and mutation status of the samples. The comparison of different NGS methods used is shown in Fig.6 and Fig. 7 for EGFR and MET copy number measurements, respectively. An interlaboratory testing of the RMs has been completed and a manuscript is in preparation describing the use of the RM 8366 for the validation of NGS and digital PCR methods.  

EGFR_Copy_Number
Figure 6. Comparison of EGFR gene copy number measurements using different NGS methods and algorithms assays used for clinical decisions for treatment of individual cancer patients.

 

MET_Gene_Copy_number
Figure 7. Comparison of MET gene copy number measurements using different NGS methods and algorithms assays used for clinical decisions for treatment of individual cancer patients.


Created June 30, 2016, Updated August 3, 2018